Detecting Cancer Cells in Blood Can Predict Melanoma Outcomes
Author Information
Author(s): Giuseppe Palmieri, Sabrina MR Satriano, Mario Budroni, Antonio Cossu, Francesco Tanda, Sergio Canzanella, Corrado Caracò, Ester Simeone, Antonio Daponte, Nicola Mozzillo, Giuseppe Comella, Giuseppe Castello, Paolo A Ascierto
Primary Institution: Istituto Nazionale Tumori 'Fondazione Pascale', Napoli, Italy
Hypothesis
Can serial detection of circulating malignant cells in melanoma patients improve prognostic predictions?
Conclusion
The study found that the presence of circulating malignant cells in blood is associated with poorer outcomes in melanoma patients.
Supporting Evidence
- Detection of at least one circulating mRNA marker indicated the presence of circulating malignant cells.
- A significant correlation was found between the number of PCR-positive assays and the rate of disease recurrences.
- Presence of circulating malignant cells in multiple blood samples was linked to poorer disease-free and overall survival.
Takeaway
If doctors find cancer cells in the blood of melanoma patients, it might mean the cancer is more serious and could come back.
Methodology
The study used a multi-marker RT-PCR assay on blood samples taken from melanoma patients at diagnosis and every six months for two years.
Potential Biases
Potential bias in patient selection and follow-up duration.
Limitations
The study was limited to a specific cohort of melanoma patients and may not generalize to all patients.
Participant Demographics
149 melanoma patients, predominantly female, median age 48 years, with disease stages I to III.
Statistical Information
P-Value
0.007
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website